在A股医药板块的起伏中，两条先后扬升的股价曲线，将舒泰神（300204）与昭衍新药（603127）共同推至聚光灯下。两家公司看似业务迥异，却由冯宇霞、周志文夫妇共同执掌。得益于股价节节攀升，冯宇霞、周志文夫妇的身家随之暴涨，成为市场瞩目的焦点。一手创新药，一手“实验猴”，冯宇霞、周志文夫妇的资本布局堪称精妙。舒泰神押注于前沿创新药研发，路径险峻，却可能换来颠覆性的回报；昭衍新药素有“猴茅”之称，...
Source Link在A股医药板块的起伏中，两条先后扬升的股价曲线，将舒泰神（300204）与昭衍新药（603127）共同推至聚光灯下。两家公司看似业务迥异，却由冯宇霞、周志文夫妇共同执掌。得益于股价节节攀升，冯宇霞、周志文夫妇的身家随之暴涨，成为市场瞩目的焦点。一手创新药，一手“实验猴”，冯宇霞、周志文夫妇的资本布局堪称精妙。舒泰神押注于前沿创新药研发，路径险峻，却可能换来颠覆性的回报；昭衍新药素有“猴茅”之称，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.